Davenport & Co
SBIO icon

Davenport & Co’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Davenport & Co’s Portfolio SBIO Stock Details SBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$612K Sell
10,500
-600
-5% -$39.1K ﹤0.01% 927
2026
Q2 		$718K Hold
11,100
– – ﹤0.01% 876
2026
Q1 		$581K Hold
11,100
– – ﹤0.01% 877
2025
Q4 		$569K Sell
11,100
-474,312
-98% -$21.9M ﹤0.01% 861
2025
Q3 		$18.9M Sell
485,412
-200,225
-29% -$6.88M 0.1% 171
2025
Q2 		$20.8M Sell
685,637
-62,485
-8% -$1.79M 0.11% 155
2025
Q1 		$21.3M Sell
748,122
-21,349
-3% -$675K 0.12% 152
2024
Q4 		$25.4M Sell
769,471
-291
-0% -$11K 0.14% 140
2024
Q3 		$28.7M Sell
769,762
-1,138
-0.1% -$41.5K 0.16% 132
2024
Q2 		$25.7M Sell
770,900
-289
-0% -$9.68K 0.16% 136
2024
Q1 		$27.5M Buy
771,189
+83,403
+12% +$2.89M 0.17% 136
2023
Q4 		$22.7M Sell
687,786
-125
-0% -$3.36K 0.15% 134
2023
Q3 		$18.7M Sell
687,911
-3,242
-0.5% -$97.6K 0.14% 137
2023
Q2 		$21.8M Buy
691,153
+2,137
+0.3% +$66.4K 0.16% 131
2023
Q1 		$18.7M Buy
689,016
+77,616
+13% +$2.34M 0.15% 138
2022
Q4 		$18.5M Buy
+611,400
New +$18.4M 0.15% 136
2015
Q4 		– Sell
-42,587
Closed -$1.19M – 607
2015
Q3 		$1.19M Buy
+42,587
New +$1.49M 0.02% 248

Other funds holding SBIO

FFAS
FIG Financial Advisory Services Oklahoma City, Oklahoma $165M AUM 16.79% 1-Year Est. Return
Independent Financial Group
Independent Financial Group San Diego, California $5.51B AUM 33.52% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
RIA
Rhodes Investment Advisors Fort Worth, Texas $141M AUM 26.5% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return
TCM
Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return

Davenport & Co's SBIO Position: Q3 2026 in Review

Davenport & Co reduced its ALPS Medical Breakthroughs ETF (SBIO) stake by 5.4% in Q3 2026, selling an estimated $39.1K and leaving 10,500 shares worth $612K. The position accounts for ﹤0.01% of the portfolio, ranked #927.

Davenport & Co first reported a position in SBIO in Q3 2015 and has held it in 17 quarters since. The position peaked at $28.7M in Q3 2024. 8 funds tracked by Wall St. Rank hold SBIO as of Q3 2026.

  • Davenport & Co held 10,500 shares of ALPS Medical Breakthroughs ETF worth $612K as of Q3 2026.
  • Davenport & Co sold 600 ALPS Medical Breakthroughs ETF shares in Q3 2026, an estimated $39.1K.
  • ALPS Medical Breakthroughs ETF made up ﹤0.01% of Davenport & Co's portfolio in Q3 2026, its #927 holding.
  • Davenport & Co first reported a position in ALPS Medical Breakthroughs ETF in Q3 2015 and has held it in 17 quarters since.
  • Davenport & Co's ALPS Medical Breakthroughs ETF position peaked at $28.7M in Q3 2024.
  • 8 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q3 2026.

Based on Davenport & Co's 13F filing for Q3 2026, filed 14 Oct 2026.